We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals

17 hedge funds and large institutions have $3.57M invested in Armata Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less funds holding

Funds holding: 1917 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

55% less capital invested

Capital invested by funds: $7.91M → $3.57M (-$4.34M)

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
2
Reduced
Closed
9
Calls
Puts
Net Calls
Net Calls Change

ARMP Hedge Fund Activity: Q2 2016 in Review

17 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2016, worth a combined $3.57M — down 55% from $7.91M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ARMP and 7 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.51M. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.28M sold.

  • 17 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2016, down from 19 in Q1 2016.
  • Funds reported $3.57M of Armata Pharmaceuticals stock for Q2 2016, down 55% quarter-over-quarter.
  • 7 funds opened new Armata Pharmaceuticals positions in Q2 2016 and 9 closed out, a net change of -2 holders.
  • The largest Armata Pharmaceuticals buyer in Q2 2016 was Sabby Management, an estimated $1.51M added.
  • The largest Armata Pharmaceuticals seller in Q2 2016 was Goldman Sachs, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2016.